Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CDX 005

Drug Profile

CDX 005

Alternative Names: 2019-nCoV vaccine - Codagenix/Serum Institute of India; CDX-005; Coronavirus vaccine - Codagenix/Serum Institute of India; COVID-19 vaccine - Codagenix/Serum Institute of India; SARS-CoV-2 Vaccine - Codagenix/Serum Institute of India

Latest Information Update: 26 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Codagenix; Serum Institute of India
  • Class Antivirals; Attenuated vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 22 Sep 2020 Serum Institute of India in collaboration with Codagenix plans a phase I for COVID-2019 infections before the end of 2020
  • 17 Aug 2020 Codagenix plans phase I clinical trial in COVID-2019 infections in the UK (Intranasal)
  • 18 Jun 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA and India (Intranasal) before June 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top